Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

SLGL
Sol-Gel Technologies Ltd.
stock NASDAQ

At Close
Aug 20, 2026 3:59:57 PM EDT
78.98USD+0.496%(+0.39)28,596
60.60Bid   95.65Ask   35.05Spread
Pre-market
0.00USD-100.000%(-78.59)0
After-hours
Aug 20, 2026 4:00:30 PM EDT
78.50USD-0.614%(-0.49)330
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 22, 2021
04:05PM EST  Sol-Gel Technologies to Participate in Upcoming LifeSci Partners   GlobeNewswire Inc
Dec 21, 2021
07:35AM EST  Sol-Gel: FDA Intends To Conduct Pre-approval Inspection Of Production Site For EPSOLAY During The Week Of Feb 14   RTTNews
07:03AM EST  FDA Informs Sol-Gel It Intends To Conduct A Pre-Approval Inspection Of The Production Site For EPSOLAY During The Week Of February 14th, 2022   Benzinga
07:00AM EST  -- FDA informs Sol-Gel that it intends to conduct a pre-approval inspection of the production site for EPSOLAY during the week of February 14th, 2022   GlobeNewswire Inc
Nov 15, 2021
01:20PM EST  HC Wainwright & Co. Maintains Buy on Sol-Gel Technologies, Lowers Price Target to $20   Benzinga
Nov 12, 2021
01:18PM EST  UPDATE: Raymond James On Sol-Gel Price Target Trim: Positive On Recent FDA Approval Of TWYNEO Which Prompted $3.5M Upfront Payment From Galderma; Believes Co. To Be 'Relatively Derisked With A Solid Risk/Reward Profile' With Consistent Cash Inflows   Benzinga
07:32AM EST  Raymond James Maintains Strong Buy on Sol-Gel Technologies, Lowers Price Target to $21   Benzinga
Nov 11, 2021
08:03AM EST  The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts   Benzinga
07:12AM EST  Sol-Gel Technologies Q3 EPS $0.05 Up From $(0.37) YoY, Sales $8.80M Up From $2.12M YoY   Benzinga
07:00AM EST  Sol-Gel Technologies Reports Third Quarter   GlobeNewswire Inc
Nov 9, 2021
07:05AM EST  Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Jefferies London Healthcare Conference, taking place in-person on November 16th and 17th, 2021.   GlobeNewswire Inc
Nov 4, 2021
07:47AM EDT  Sol-Gel Technologies Announces Sale Of Generic Dermatology Portfolio To Partner Padagis For $21M   Benzinga
07:30AM EDT  - Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs   GlobeNewswire Inc
Sep 22, 2021
07:41AM EDT  Sol-Gel Technologies To Present At Upcoming Cantor Virtual Global Healthcare Conference Sept. 30   Benzinga
07:30AM EDT  Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Cantor Global Healthcare Conference, taking place virtually from September 27th 30th, 2021.   GlobeNewswire Inc
Sep 9, 2021
08:30AM EDT  Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in H.C. Wainwrights 23rd Global Investment Conference.   GlobeNewswire Inc
Aug 4, 2021
07:14AM EDT  Sol-Gel Technologies Q2 EPS $(0.35) Misses $(0.21) Estimate, Sales $928.00K Miss $2.89M Estimate   Benzinga
07:05AM EDT  Sol-Gel Technologies Reports Second Quarter 2021 Financial Results   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 4, 2021   Benzinga
Jul 28, 2021
06:21AM EDT  HC Wainwright & Co. Maintains Buy on Sol-Gel Technologies, Raises Price Target to $21   Benzinga
Jul 27, 2021
11:13AM EDT  Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris   Benzinga
11:13AM EDT  Sol-Gel Technologies Announces FDA Approval Of TWYNEO   Benzinga
11:13AM EDT  Sol-Gel Technologies Shares Halted, News Pending   Benzinga
Jul 20, 2021
07:05AM EDT  Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.   GlobeNewswire Inc
Jul 12, 2021
06:11AM EDT  HC Wainwright & Co. Maintains Buy on Sol-Gel Technologies, Lowers Price Target to $20   Benzinga
Jun 28, 2021
05:15AM EDT  Sol-Gel Technologies and Galderma Announced Exclusive Licenses for the Commercialization of EPSOLAY and TWYNEO in the U.S.   Benzinga
05:10AM EDT  Sol-Gel Announces Pipeline Update and Future Development Plans   GlobeNewswire Inc
05:07AM EDT  Sol-Gel And Galderma Announce Licenses For Commercialization Of EPSOLAY And TWYNEO In U.S.   RTTNews
05:00AM EDT  Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY(r) and TWYNEO(r) in the United States   Business Wire
May 27, 2021
07:00AM EDT  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (Sol-Gel), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences:   GlobeNewswire Inc
May 13, 2021
07:07AM EDT  Sol-Gel Technologies Q1 EPS $(0.18) Up From $(0.33) YoY, Sales $700.00K Down From $3.46M YoY   Benzinga
07:05AM EDT  - Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY and TWYNEO   GlobeNewswire Inc
Apr 27, 2021
10:04AM EDT  Sol-Gel Technologies Provides Update On FDA Review Of EPSOLAY   Benzinga
10:03AM EDT  Sol-Gel Technologies Provides Update on FDA Review of   GlobeNewswire Inc
07:41AM EDT  The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout   Benzinga
Apr 24, 2021
09:24AM EDT  The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx   Benzinga
Mar 17, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes   Benzinga
Mar 16, 2021
08:17AM EDT  The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study   Benzinga
Mar 12, 2021
07:36AM EST  The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs   Benzinga
Mar 4, 2021
07:14AM EST  Sol-Gel Technologies FY20 EPS $(1.30), Down from $(1.26) YoY, Sales $8.8M   Benzinga
07:05AM EST  Epsolay and Twyneo PDUFA goal dates set for April 26, 2021 and August 1, 2021 respectively   GlobeNewswire Inc
Mar 2, 2021
08:30AM EST  Sol-Gel Technologies Granted US Patent Titled 'Method for treatment of rosacea in patients aged 65 years and older'   Benzinga
Feb 24, 2021
07:05AM EST  Sol-Gel Technologies(NASDAQ: SLGL), (Sol-Gel), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.   GlobeNewswire Inc
Dec 7, 2020
07:14AM EST  Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo for the Treatment of Acne Vulgaris   Benzinga
07:14AM EST  Sol-Gel Announces FDA Acceptance For Filing Of NDA For Twyneo For Acne Vulgaris; PDUFA Goal Date Set For August 1   RTTNews
07:05AM EST  Sol-Gel Technologies Announces FDA Acceptance for Filing of New   GlobeNewswire Inc
Nov 12, 2020
08:21AM EST  Recap: Sol-Gel Technologies Q3 Earnings   Benzinga
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
07:16AM EST  Sol-Gel Technologies Q3 EPS $(0.37) Beats $(0.46) Estimate, Sales $2.12M Beat $1.82M Estimate   Benzinga
07:05AM EST  -- Epsolay PDUFA goal date set for April 26, 2021 -- Twyneo New Drug Application submitted to the U.S. FDA -- Top-line generic product revenue of $2.1 million in 3Q 2020 -- In October 2020, signed an 11th generic product collaboration agreement with Perrigo   GlobeNewswire Inc
04:18AM EST  Earnings Scheduled For November 12, 2020   Benzinga
Nov 9, 2020
07:05AM EST  Sol-Gel Technologies (NASDAQ: SLGL), (Sol-Gel), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases,today announced that the company will present at the following upcoming virtual investor conferences.   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 4, 2020
04:05PM EST  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report third quarter 2020 financial results on Thursday, November 12, 2020 at 7:05 AM ET.   GlobeNewswire Inc
Sep 10, 2020
06:04PM EDT  After Hours Market: Zumiez, Oracle, Peloton Interactive   RTTNews
04:01PM EDT  Sol-Gel Technologies Reports FDA Acceptance For Filing Of New Drug Application For Epsolay For Treatment Of Inflammatory Lesions Of Rosacea; PDUFA Date Set For Apr. 26, 2021   Benzinga
04:01PM EDT  Sol-Gel Technologies Announces FDA Acceptance for Filing of New   GlobeNewswire Inc
Sep 8, 2020
07:05AM EDT  Sol-Gel Technologies (NASDAQ: SLGL), (Sol-Gel), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases,today announced that the company will present at the following upcoming virtual investor conferences.   GlobeNewswire Inc
Sep 3, 2020
07:05AM EDT  Sol-Gel Technologies Collaboration Partner Filed First-to-File   GlobeNewswire Inc
Aug 6, 2020
09:41AM EDT  Sol-Gel Technologies Q2 EPS $(0.31) Beats $(0.34) Estimate, Sales $1.13M Miss $3.04M Estimate   Benzinga
07:08AM EDT  -- New Drug Application for Epsolay Submitted; Twyneo New Drug Application on track for 2H 2020 -- Top-line generic product revenue of $1.1 million in 2Q 2020 -- Launch of additional generic product expected in 2Q 2021   GlobeNewswire Inc
Jul 29, 2020
07:05AM EDT  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2020 financial results on Thursday, August 6, 2020 at 7:05 AM ET.   GlobeNewswire Inc
Jul 28, 2020
07:10AM EDT  Sol-Gel Technologies Says Partnered Generic Product Expected To Launch In Q2 Of 2021   Benzinga
07:05AM EDT  Sol-Gel Technologies Partnered Generic Product Expected to Launch   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC